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predominant in the Mediterranean area [5]. This 
finding suggests ongoing spread and/or emergence 
of cephamycinase genes, and underscores the necessity 
of monitoring multiply-resistant strains in order to 
minimize the risk of therapeutic failure due to 
resistance against established antibiotic combinations, 
e.g. a third-generation cephalosporin plus an amino- 
glycoside. 
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Comparative activities of amoxycillin and 10 other 
oral drugs against penicillin-susceptible and -resistant 
Streptococcus pneumoniae strains recently isolated 
in Italy 
Clin Mirrobiol infect 1998; 4: 170-173 
Streptococcus pneumoniae remains a leading cause of 
morbidity and mortality despite the availability of 
several antimicrobial agents that perform adequately in 
vitro. This pathogen is known to cause a broad 
spectrum of infections, with pneumonia, otitis media, 
septicemia and meningitis being the most common 
[1,21. The incidence of penicillin-resistant, multiply- 
resistant pneumococci is increasing worldwide. 
Although for non-meningitic infections high-dose 
penicillin remains clinically effective against strains that 
are resistant in vitro, this type of treatment is risky and 
may not aIways be successful [3,4]. Previous studies 
[5,6] have demonstrated that amoxycdlin can display 
useful potency in vitro against penicillin-resistant 
pneumococci. In order to confirm this finding in the 
pneumococcal population circulating in Italy, the in 
vitro activities of amoxycillin and amoxycillin/ 
clavulanate in comparison with those of other oral 
antibiotics has been assessed on a substantial number of 
strains. 
A total of 798 Streptococcus pneumoniae strains, 
including 49 penicillin-resistant strains (29 displaying 
low- and 20 high-level resistance according to the 
breakpoints specifically proposed for S. pneurnoniae by 
the National Committee for Clinical Laboratory 
Standards (NCCLS) [7] (see also footnote 'a' in Table l),  
isolated from 1993 to 1996 in nine laboratories in 
central and northern Italy (Genoa, Parma, Berganio, 
Turin, Perugia, Vercelli, Bologna, Florence and Milan) 
were tested. Consecutive pneumococcal strains (with 
duplicate isolates from same patient episodes excluded) 
from all sites were dispatched to the Institute of 
Microbiology of Genoa, where the microorganisms 
were stored in 10% glycerol at -70°C. The in vitro 
activity of selected antibiotics against all strains was 
studied at the same time after subculturing the micro- 
organisms twice on blood agar plates. s. pneumoniae 
ATCC 49619 was included as control strain. 
Amoxycillin and clavulanic acid (used in associa- 
tion in the ratio 2 : 1) were obtained from SmithKline 
Beecham Pharmaceuticals (Milan, Italy). Cefixime, 
cefaclor, erythromycin, clarithromycin, azithromycin, 
co-trimoxazole, ofloxacin and ciprofloxacin were 
supplied by their respective manufacturers. Minimal 
inhibitory concentrations (MICs) were determined by 
microdilution assay in cation-adjusted Mueller-Hinton 
broth with 5% lysed horse blood, as detailed in the 
NCCLS [7] guidelines. 
Under these experimental conditions, clavulanic 
acid did not decrease the MIC values of amoxycillin, as 
reported elsewhere for penicillin [ 8 ] .  
Against the 749 penicillin-susceptible S. przerr- 
moniae isolates amoxycillin showed the highest activity 
in terms of MICro (0.06 mg/L), while the comparative 
agents displayed MIC9o values (mg/L) ranging from 0.5 
for cefixime to 8 for co-trimoxazole (Table 1). The in 
vitro potency of amoxycillin was also confirmed when 
the data were translated into percentages of susceptible 
strains. The two drugs inhibited, in fact, 100% of the 
isolates tested, while the comparator agents were 
efficacious on 80% (co-trimoxazole) or 89% (erythro- 
mycin, clarithromycin, azithromycin) of the penicillin- 
susceptible strains. 
Concise  C o m m u n i c a t i o n s  1 7 1  
Table 1 
Microorganism Antibiotics Range MICso MIC9o Percentage susceptibleb 
In vitro activity of amoxycillin and other 10 antibiotics against Streptococcus pneumoniae 
S. pneumoniae PEN-S" Penicillin 
(749) Amoxycillin 
Amoxycillin/clavulanatec 
Cefiximed 
CefacloP 
Erythromycin 
Clarithromycin 
Azithromycin 
Co-trimoxazole 
Ofloxacin 
Ciprofloxacind 
S. pneumoniae PEN-I" Penicillin 
(29) AnioxycilIin 
Amoxycillin/clavulanatec 
Cefiximed 
Cefaclord 
Erythromycin 
Clarithromycin 
Azithromycin 
Co-trimoxazole 
Ofloxacin 
Ciprofloxacind 
S. pneumoniae PEN-R" Penicillin 
(20) Amoxycillin 
Amoxycillin/clavulanatec 
Cefiximed 
Cefaclor" 
Erythromycin 
Clarithromycin 
Azithromycin 
Co-trimoxazole 
Ofloxacin 
Ciprofloxacind 
50.015-0.06 
50.03-0.12 
50.03-0.12 
50.03-1 
50.03-1 
50.06 to >64 
50.06 to >64 
50.06 to 264  
50.25-8 
0 .254  
0.5-8 
0.12-1 
50.06-1 
50.06-1 
1 to >32 
0.5 to >32 
0.12 to >64 
10.06 to >64 
0.5 to >64 
0.25-8 
2 4  
0.5-4 
2 4  
0.5-4 
0.5-4 
32 to >32 
8 to >32 
0.12 to >64 
0.12 to >64 
0.5 to >64 
0.5-16 
2-4 
1 4  
0.03 
0.06 
0.06 
0.5 
0.5 
0.25 
0.25 
0.25 
0.5 
2 
2 
0.25 
0.12 
0.12 
8 
16 
0.25 
0.25 
0.5 
4 
2 
2 
2 
1 
1 
>32 
32 
16 
16 
> 64 
8 
2 
4 
0.06 
0.06 
0.06 
0.5 
1 
2 
2 
2 
8 
4 
4 
1 
1 
1 
> 32 
16 
> 64 
> 64 
> 64 
4 
4 
4 
4 
2 
2 
> 32 
> 32 
> 64 
> 64 
> 64 
16 
4 
4 
100 
100 
100 
- 
- 
89 
89 
89 
80 
86 
- 
0 
62 
62 
- 
- 
52 
52 
52 
28 
83 
- 
0 
40 
40 
- 
- 
35 
35 
35 
85 
0.5 
- 
'PEN-S: penicillin susceptible (MICs 50.06 mg/L). PEN-I: penicillin intermediate (MICs 0.12-1 mg/L), penicillin resistant (MICs 
2 2  mg/L) according to NCCLS (1995). 
bBreakpoints suggested by NCCLS (1995) for S. pneumoniae in mg/L: arnoxicillin, 0.5; co-clavulanate, 0.W0.25; erythromycin, 0.25; 
clarithromycin, 0.25; azithromycin, 0.5; co-trimoxazole, 0.5/9.5; ofloxacin, 2. 
'MICs for amoxycillin/clavulanate are expressed as the amoxycillin component. 
dBreakpoints for these drugs against S. pneumoniae are not available in the NCCLS (1995) guidelines. 
Towards the 29 low-level penicillin-resistant S. 
pneumoniae strains (MIC90 1 mg/L), amoxycillin 
remained the most powerful agent among the drugs 
assayed, with an MICw (mg/L) of 1, versus >32 for 
cefixime, 16 for cefaclor, 4 for co-trimoxazole, 4 for 
ofloxacin and ciprofloxacin, and >64 for erythro- 
mycin, clarithromycin and azithromycin. 
Against the 20 high-level penicillin-resistant strains 
(MI& 4 mg/L), amoxycillin showed MICw values of 
2 (mg/L) versus >32 for cefixime and cefaclor, 16 for 
co-trimoxazole, 8 for ofloxacin and ciprofloxacin, and 
> 64 for erythromycin, clarithromycin and azithro- 
mycin. 
In other surveys, amoxycillin MICs for low-level 
resistant and fully resistant pneumococci have been 
shown to be one or two dilutions lower than those of 
penicillin [5,6]. The present results confirm this finding 
in a substantial collection of clinical strains. 
As expected [5,6], none of the oral cephalo- 
sporins tested were more active than amoxycillin against 
either penicillin-susceptible or penicillin-resistant S. 
pneumoniae. 
Resistance rates to erythromycin and co- 
trimoxazole among the 749 strains were 11% and 20% 
respectively. A higher proportion of the high-level 
penicillin-resistant pneumococci showed reduced 
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Table 2 
to penicillin, erythromycin and co-trimoxazole 
Susceptibility of S. pmurnoniae isolated during 1993-96 
1993 1994 1995 1996 
No. of strains 312 128 151 207 
Penicillin ( N  (‘%)) 
5 295 (97) 121 (94.6) 142 (93.1) 191 (92.3) 
I 9 (2.9) 4 (3.1) 3 (2) 13 (6.3) 
li 8 (2.6) 3 (2.3) 6 (3.6) 3 (1.4) 
I+R 17 (5.5) 7 (5.4) 9 (5.9) 16 (7.7) 
Erythromycin (S (“A)) 
S 293 (94) 120 (93.8) 123 (81.5) 159 (77) 
I 7 (2.2) 3 (2.3) 3 (1.9) 1 (0.5) 
R 12  (3.8) 6 (4.7) 25 (16) 47 (22.5) 
I+R 19 (6) 9 (7) 28 (18.5) 48 (23) 
Co-trimoxazole (S (“h)) 
S 256 (82) 105 (82) 117 (77.5) 133 (64) 
I 42 (13) 10 (7.8) 8 (5.3) 20 (10) 
I< 11 (4.5) 13 (10.2) 26 (17.2) 54 (26) 
I f K  56 (18) 23 (18) 34 (22.5) 74 (36) 
S, susceptible; I ,  intermediate; R, resistant. 
susceptibility to the macrolide (65% resistant) and co- 
trimoxazole (95.5% resistant) and the same was true, to 
a lesser extent, of low-level penicillin-resistant strains 
(48% resistance to erythromycin, clarithromycin and 
azithromycin and 72% to co-trimoxazole). 
The great majority of the strains tested had only 
borderline susceptibility to ofloxacin and ciprofloxacin, 
as reported in other studies [9-131. As previously 
described [S, 111, resistance to fluoroquinolones was not 
associated with resistance to penicillin. In fact, a 
significant reduction of susceptibility to ofloxacin was 
not observed among low-level penicillin-resistant 
(83%) and high-level penicillin-resistant (85%) when 
compared to penicillin-susceptible (86%) S. pneumoniae 
strains. 
In Italy the circulation of penicillin-resistant S. 
pneumoniae is modest, as previously described [14]. The 
incidence of this trait in the strains studied did not vary 
substantially, changing from 5.5% in 1993 to 7.7% in 
1996, as reported in Table 2. In this country, however, 
the problem of S. pneumoniae resistance is compounded 
by the fact that pneumococci resistant to cefotaxime 
and ceftriaxone (MIC 1 mg/L) have already appeared 
1141 and represent 20% of the 20 penicillin-resistant 
strains and 6.8% of the 29 penicillin-intermediate 
strains (data not shown). This worrying evolution may 
be the consequence of the peculiar patterns of paren- 
teral antibiotic prescribing habits prevailing in Italy 
both in the hospital and in the community practice 
1151. 
Concurrent increased resistance to erythromycin 
and co-trimoxazole has been detected with rates 
ranging from 6% and 18% in 1993 to 23% and 36% in 
1996 (Table 2) [14]. Increasing resistance to the 
macrolides in Italy represents an emerging problem not 
only for S.  pneumoniae but also for S. pyogener [16]. 
The in vitro activity of amoxicillin against most S. 
pneumoniae strains circulating in Italy militates for a 
possible role of this drug in the empirical treatment of 
mild upper and lower respiratory tract infections 
acquired in the community, where it may represent an 
appropriate and more potent alternative to penicillin. 
Given the fact that generally the therapy of these 
conditions is started empirically, and since a number 
of P-lactamase-producing pathogens (Haemophilrrs 
inzuenzae, Moraxella catarrhalis, Staphylococcus anreus, 
fdebsiella pneumoniae) may play a concomitant etiologic 
role [I 71, adoption of amoxycillin/clavulanate may 
represent a more prudent and equally effective choice. 
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iatrogenic factors, e.g. antibiotic therapy, although in 
most cases of vaginal flora changes the cause is 
unknown. Lactobacilli are the predominant organisms 
in the vaginas of most women, with an important role 
in maintaining a stable ecosystem. The production of 
hydrogen peroxide by lactobacilli i j proposed to be 
important for that balance. In vitro, lactobacilli can 
inhibit the growth of pathogenic microorganisms 
which may invade the vagina, including Escherichia coli, 
Candida albicans, Gardnerella vaginalis and Mobiluncus spp. 
Many other mechanisms have been proposed to explain 
the role of lactobacilli in protecting the vagina from 
invading pathogenic organisms, e.g. the low vaginal pH 
generated by lactic acid production, a:nd competition of 
the lactobacilli with other pathogens for adherence to 
vaginal epithelial cells or cell receptors. 
The aims of the present study were to compare the 
interpretations of Gram-stained sml-ars by a trained 
observer and a trainee, and to confirm the relationship 
between the presence or absence of lactobacilli and 
various vaginal infections. The subjects were 746 
women who had attended for conixaceptive advice. 
Vaginal smears from all of the women were available, 
vaginal cultures were available from 696 (93.3%) and 
full data for analysis were available fiom 691 (92.6%). 
Vaginal fluid was collected from the Inucosa on cotton 
swabs; these were then rolled over glass slides and 
the preparations were fixed with gentle heating. The 
smears were Gram-stained using carbol fuchsin as 
a counter-stain and examined under oil immersion 
( ~ 1 0 0 )  by one venereologist (obsewer A) and one 
trainee in microbiology (observer E;). Each observer 
was asked to interpret the slides :iccording to the 
criteria of Spiegel et a1 [2]. 
Cultures for human papilloma virus (HPV), 
Mycoplasma horninis, Ureaplasrna urralyticum, Gardnerella 
vaginalis and anaerobic bacteria were made as described 
elsewhere [3]. 
The results showed excellent to good agreement 
between the two observers regarding the dominance or 
deficiency of lactobacilli, vaginal flora changes like 
those seen in bacterial vaginosis (BV) and the presence 
of clue cells (kappa index 0.80, 0.78, 0.54 and 0.56) 
(Table 1). The consistency of detection of a flora 
change was excellent to good when the two observers' 
results were compared (kappa index 0.79, 0.52, 0.69 
and 0.40, respectively; Table 1). 
Vaginal flora changes and reproducibility of interpretation 
of Gram-stained vaginal smears 
Deficiency of lactobacilli, as detected by Gram- 
stained vaginal smears was significantly associated with 
Clin Microbiol Infect 1998; 4: 173-175 a high frequency ofHPV (OR=2.0,95% CIxl.1-3.6). 
G. vapinalis, M .  horninis and U. urealyticum occurred 
The vagina is characterized by a finely balanced 
microbial ecosystem [ l ]  which can be altered by a 
number of factors, such as hormonal therapy and other 
significantly more often in the women lacking lacto- 
bacilli than in those with lactobacilh (Table 2). The 
association of these organisms with deficiency of 
